UK MHRA Considers Additional Inspection Fees For Non-Compliance
The UK medicines regulator is planning to levy additional fees to recover the costs associated with the extra time spent by inspectors in following up or reviewing non-compliance cases referred for further action.
You may also be interested in...
The MHRA is testing the feasibility of appointing eligible external consultants to be its eyes and ears when it comes to checking up on drug companies that have failed to meet good manufacturing and distribution practice requirements.
A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection.
EU regulators have developed a draft good practice guide explaining how stakeholders can make use of the Metadata Catalog of RWD Sources, which is expected to be released in late 2023, to identify appropriate sources for specific research questions.